PARIS, June 2 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, Julianne Smith, PhD, head of the Meganuclease Recombination System group at Cellectis genome surgery, and Feng Zhang, PhD, Research Director at Cellectis plant sciences have been invited to present Cellectis' results on meganucleases and genome surgery at the FASEB Summer Research Conference on Genome Engineering to be held in Steamboat Springs, Colorado, USA, on June 6-11, 2010.
Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes.
Dr Paques will discuss "Engineering Meganucleases for Genome Engineering Purposes" on June 7, 2010, at 7:00AM, during an oral session on Engineering Customized Nucleases, while Dr Smith will present "Meganucleases for Genome Surgery" on June 8, 2010, at 8:45AM, during an oral session on Nuclease-Enhanced Genome Engineering in Mammalian Cells. Dr Zhang will talk about "Modification of Plant Genomes using Engineered Meganucleases" on June 8, 2010, at 10:00AM, during an oral session on Nuclease-Enhanced Genome Engineering in Model Organisms and Plants.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets finnovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over EUR 70 million in funding since inception.
More information at www.cellectis.com
Follow us on Twitter: twitter.com/cellectis
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis
Advertisement
Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes.
Advertisement
Dr Paques will discuss "Engineering Meganucleases for Genome Engineering Purposes" on June 7, 2010, at 7:00AM, during an oral session on Engineering Customized Nucleases, while Dr Smith will present "Meganucleases for Genome Surgery" on June 8, 2010, at 8:45AM, during an oral session on Nuclease-Enhanced Genome Engineering in Mammalian Cells. Dr Zhang will talk about "Modification of Plant Genomes using Engineered Meganucleases" on June 8, 2010, at 10:00AM, during an oral session on Nuclease-Enhanced Genome Engineering in Model Organisms and Plants.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets finnovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over EUR 70 million in funding since inception.
More information at www.cellectis.com
Follow us on Twitter: twitter.com/cellectis
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis
